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CPNP
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5-fluorouracil
bacterial cytosine deaminase
ganciclovir
yeast cytosine deaminase
TK: herpes simplex type 1
thymidine kinase
calcium phosphate nanoparticles
carcinoembryonic antigen
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The global statistics regarding incidences of and deaths from gastric cancer are staggering: it has accounted for as many as 650,000 deaths per year,1 and among cancer-related
deaths, it ranks as the second leading cause, behind only lung cancer.2,3 Five-year survival
rates hover around a meager 20% since traditional chemotherapies such as 5-fluorouracil
(5-FU) and doxorubicin do not exhibit sufficient therapeutic properties in advancedstages, often when a majority of cases are diagnosed.1 Based on these dire statistics, it is
obvious that new therapies must be developed to combat this disease, and one emerging
approach is targeted suicide gene therapy.
Suicide gene therapy, where nonmammalian genes convert normally nontoxic prodrugs
into toxic forms, is a promising form of therapy that is now in Phase I clinical trials for
the treatment of prostate and colorectal cancer.4,5 Bacterial cytosine deaminase (bCD)
and herpes simplex type 1 thymidine kinase (HSV-1 TK) are two suicide genes known
for their ability to convert nontoxic 5-fluorocytosine into toxic 5-FU and nontoxic ganciclovir (GCV) into toxic phosphorylated GCV, respectively. The resulting metabolites are
integrated into the DNA and RNA of cells, leading to strand termination and eventual
cell death.6 While bCD is capable of acting as a suicide gene, it has been reported that
yeast CD (yCD) is much more powerful in this regard.7,8 Recently, a novel fusion suicide
gene was developed consisting of both yCD and HSV-1 TK, termed yCDglyTK; when
expressed in tumor cells, it performed prodrug conversion while rendering the cells more
sensitive to radiation therapy.6
Gene therapy is, of course, most effective when delivery is both efficient and safe,
especially when dealing with cancer. However, it has often proven difficult to find a balance
between efficiency and safety. For example, viral vectors, which encompass some of the
most common methods used in gene therapy due to their superior transfection efficiency,
often induce an immune response9 and can even cause patient death.10 As a result, much
recent work has been devoted to non-viral delivery methods, including cationic liposomes
and calcium phosphate nanoparticles (CPNP). While cationic liposomes show potential
regarding transfection efficiency and the size of DNA they can deliver, they can be toxic
under certain conditions.11 Conversely, Liu et al have recently shown that positively
charged CPNP can also bind negatively charged DNA effectively, and these complexes are
able to enter the cell to deliver the DNA with minimal toxicity.12
While efficient delivery of suicide genes is an attractive approach to treating gastric
cancer, lack of tumor specificity can still lead to undesirable side effects. Preferably, the
suicide genes would affect only malignant cells, while sparing normal, healthy cells. As
many cancers, namely gastric, colon, breast and ovarian, overexpress the carcinoembryonic
antigen (CEA) protein [reviewed in Ref. 13] it has come to light that selective therapy
for colorectal cancer can be achieved using a CEA promoter that drives the expression of
either bCD14 or yCD.15 In the December 2006 issue of Cancer Biology and Therapy, Liu
et al describe a method of efficiently and selectively delivering the yCDglyTK suicide gene
by placing it under the control of a CMV-enhanced CEA promoter (CV) and complexing
it with CPNP. The group envisioned that once the genes were efficiently transferred via
the CPNP, only cells expressing CEA, e.g., gastric cancer cells, would undergo cytotoxic
effects after 5-FC was administered and subsequently converted to 5-FU.
The authors report that in CV-yCDglyTK-positive SGC7901 gastric cancer cells (CEA
positive) cell viability was only 10.2%, while in CV-yCDglyTK-positive Hela cells (CEA
negative) viability was 98% following the administration of 5-FC. When CPNP were used
to deliver the suicide gene, SGC7901 cells exhibited only 25.36% viability, demonstrating
the efficiency of CPNP delivery. Intriguingly, when stably transfected CV-yCDglyTK
SGC7901 cells were mixed with untransfected SGC7901 cells, a significant “bystander
effect” occurred after five days of treatment with 5-FC. Cell death was as high as 38.5%
even when only 5% of the cells in the mixture were CV-yCDglyTK positive. In vivo
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studies further confirmed the therapeutic potential of combining
suicide genes with non-viral CPNP delivery vehicles. SGC7901
xenografts that received CPNP-CV-yCDglyTK injections showed
marked tumor regression as compared to the untransfected control
group, when both groups were treated with 5-FC.
Collectively, these results indicate that this novel, targeted system
shows promise regarding the development of therapies for gastric
cancers, or other malignancies that overexpress the CEA antigen.
Since bCDglyTK and yCDglyTK fusion gene therapies have both
been found to leave malignancies more susceptible to radiation
therapy,10,16,17 a natural next step for this group could be to utilize
5-FC, GCV and radiopharmaceuticals to investigate the possibility
of synergistic and/or radiosensitization effects within their novel
targeted system.
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